Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Long-Term Debt Repayments: 2017-2021

Historic Long-Term Debt Repayments for Aclaris Therapeutics (ACRS) over the last 4 years, with Dec 2021 value amounting to -$11.5 million.

  • Aclaris Therapeutics' Long-Term Debt Repayments was N/A to $149,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $648,000, marking a year-over-year change of. This contributed to the annual value of -$11.5 million for FY2021, which is N/A change from last year.
  • Per Aclaris Therapeutics' latest filing, its Long-Term Debt Repayments stood at -$11.5 million for FY2021, which was up 61.72% from -$30.0 million recorded in FY2019.
  • In the past 5 years, Aclaris Therapeutics' Long-Term Debt Repayments ranged from a high of $648,000 in FY2018 and a low of -$30.0 million during FY2019.
  • For the 2-year period, Aclaris Therapeutics' Long-Term Debt Repayments averaged around -$20.7 million, with its median value being -$20.7 million (2019).
  • In the last 5 years, Aclaris Therapeutics' Long-Term Debt Repayments surged by 730.77% in 2018 and then slumped by 4,729.63% in 2019.
  • Yearly analysis of 4 years shows Aclaris Therapeutics' Long-Term Debt Repayments stood at $78,000 in 2017, then skyrocketed by 730.77% to $648,000 in 2018, then slumped by 4,729.63% to -$30.0 million in 2019, then reached -$11.5 million in 2021.